Article ID Journal Published Year Pages File Type
8924747 Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2018 9 Pages PDF
Abstract
Disease control was excellent for patients who received SBRT for early-stage NSCLC, and this series represents the largest single-institution experience from the United States on SBRT for early-stage inoperable NSCLC. Higher pretreatment FDG-PET SUVmax was associated with increased risk of any recurrence, and the 50 Gy in 5 fractions dose prescription was associated with increased risk of local recurrence.
Related Topics
Health Sciences Medicine and Dentistry Critical Care and Intensive Care Medicine
Authors
, , , , , , , , , , , , , , , , , , ,